YC S26's Rise Reforming Turns Biogas into Chemicals
28 Jul 2026
Rise Reforming, a member of Y Combinator's S26 batch, is building on-site technology to convert stranded biogas from wastewater plants, farms, and landfills into valuable chemicals like dimethyl ether (DME), methanol, and dimethyl carbonate (DMC).
The Opportunity
The company's pitch rests on two figures: an estimated $20 billion in annual value from chemicals producible from U.S. biogas, and the fact that 60% of U.S. biogas is currently wasted or flared in low-margin applications. If these estimates hold up, they point to a substantial and underexploited market for biogas valorization technology.
From Incubator to Pre-Seed
Rise Reforming's timeline shows a compressed early-stage trajectory:
- August 2025 — The company was established at Illinois Institute of Technology's incubator lab, with Nina Kritikos joining as its first hire.
- December 2025 — Rise Reforming closed a $650,000 pre-seed round to fund proof-of-concept work, IP filing, and pilot plant planning.
- April 2026 — The company completed its proof-of-concept, achieving over 1,800 hours of stable syngas production.
Early Commercial Signals
Beyond the technical milestone, Rise Reforming has lined up some commercial groundwork: a binding supply agreement and multiple MOUs with biogas producers, plus a conditional DME offtake agreement for its first commercial unit. Together, these suggest the company is trying to de-risk both its feedstock supply and its initial customer pipeline before scaling to pilot production.
What's Still Unclear
The report notes several gaps that limit a full picture of the company's progress:
- No details on the specific technology or chemical process used for conversion.
- No information on the size, location, or timeline of the planned pilot plant.
- No named parties behind the supply agreement, MOUs, or offtake deal.
- No visibility into team size beyond the first hire, or founder backgrounds.
- No methodology disclosed for the $20 billion market estimate or the 60% flaring figure.
- It's unclear whether pre-seed investors were disclosed beyond the total funding amount.
Risks to Watch
A few factors suggest the company's commercial path is not yet fully secured:
- The DME offtake agreement is conditional, meaning committed revenue is not guaranteed.
- The technology remains at proof-of-concept stage, with the pilot plant still in planning — commercial-scale performance has not yet been demonstrated.
- Some biogas supply commitments rely on non-binding MOUs, which could leave gaps in the feedstock pipeline until finalized.
Why Founders Should Care
For founders in energy, chemicals, or adjacent deep-tech spaces, Rise Reforming's trajectory offers a few probabilistic takeaways:
- The reported market size and waste percentage may indicate a meaningfully underexploited opportunity in biogas valorization, though the underlying methodology is not disclosed.
- The path from incubator lab to pre-seed funding to a proof-of-concept milestone in under a year could suggest a workable early-stage roadmap for hardware and chemistry-focused startups, though execution risk remains high at this stage.
- Locking in a binding supply agreement alongside MOUs before reaching pilot-scale operation likely reflects the value of building commercial relationships early, even if some of those commitments remain non-binding.
- The conditional nature of the offtake agreement suggests founders in similar deep-tech categories may need to plan for extended timelines before securing firm, unconditional customer commitments.
As with many early-stage deep-tech ventures, Rise Reforming's next phase — pilot plant construction and conversion of its conditional offtake into firm revenue — will be the real test of whether its proof-of-concept results translate into a scalable business.